The First Drug Approved for Sleep Apnea: What Tirzepatide Actually Does
In December 2024 a weight-loss drug became the first medicine approved to treat obstructive sleep apnea. The trial results are genuinely striking, and the indication is narrower than the headlines suggested.
On 20 December 2024 the FDA approved tirzepatide, sold as Zepbound, for moderate-to-severe obstructive sleep apnea in adults with obesity. It was the first drug ever approved to treat the condition.
That is a genuine milestone in a field where the only options had been machines, appliances and surgery. It is also being widely misreported, so it is worth setting out precisely what was shown and for whom.
What the trial found
SURMOUNT-OSA randomised 469 adults with moderate-to-severe obstructive sleep apnea and obesity, across two parallel studies: one in people unable or unwilling to use positive airway pressure therapy, and one in people already using PAP and planning to continue.
Participants received tirzepatide at a maximum tolerated dose of 10 mg or 15 mg, or placebo, for 52 weeks.
The headline result: a mean reduction in apnea-hypopnea index of 27.4 events per hour on tirzepatide, against 4.8 on placebo.
In the group not using PAP therapy, that worked out at roughly 25 fewer breathing disruptions per hour versus five on placebo — around five times the effect. In the group already on PAP, about 72% saw their AHI fall by at least half.
For context, an AHI reduction of 27 events per hour is large. Someone entering the trial at 40 events per hour — comfortably severe — could plausibly finish in the mild range.
What it does not show
It is not a cure. A large reduction in AHI is not the same as elimination, and most participants still had measurable apnea at the end. The framing that matters clinically is severity reduction, not resolution.
It is not approved for sleep apnea generally. The indication is moderate-to-severe obstructive sleep apnea in adults with obesity. If you have apnea and are not in that group, this approval does not apply to you, and the trial says nothing about whether it would work.
It is not a straightforward CPAP replacement. One arm of the trial was specifically people who were staying on PAP therapy, and they benefited too. The result supports it as a treatment that reduces severity, sometimes alongside existing therapy rather than instead of it.
It requires ongoing treatment. This is a weight-driven mechanism, and weight regain after stopping GLP-1 receptor agonists is well documented. There is no reason to expect the apnea benefit to persist if the weight does not.
Why it works
Not mysteriously. Excess weight, particularly fat deposited around the neck and in the tongue and pharyngeal tissues, narrows the upper airway and makes it more collapsible. Reduce that and the airway behaves better.
What is new is not the mechanism but the magnitude and reliability of the weight change. Advising weight loss for apnea is decades old; the advice was limited by how few people achieved and maintained meaningful loss. A drug that produces substantial, sustained reduction changes the practical value of a long-standing recommendation. How weight relates to the airway.
The practical caveats
Side effects are mostly gastrointestinal — nausea, vomiting, diarrhoea, constipation — and are the common reason people stop. There are less common but more serious considerations, including pancreatitis and gallbladder disease, and specific contraindications. This is a prescribing conversation, not a summary on a website.
Cost and access are substantial barriers, and coverage for the apnea indication specifically varies.
You still need to be diagnosed and monitored. Starting a drug for apnea requires knowing you have apnea and how severe it is, which means a sleep study. And because the effect is a reduction rather than elimination, retesting afterwards matters — you need to know what your AHI actually is now, not assume it is fine.
Who this is genuinely relevant to
Adults with obesity and diagnosed moderate-to-severe obstructive sleep apnea, particularly those who cannot tolerate CPAP, or who are on CPAP and want to reduce severity alongside it.
For that group it is a real option that did not exist two years ago, and it is worth raising with the clinician managing your apnea.
For everyone else — people with mild apnea, people without obesity, people who snore but have never been tested — this is not your treatment, and the more useful next step is establishing what you actually have. Snoring versus apnea, and what a sleep test involves.
The wider point
The approval is a reminder that apnea severity is not fixed. It responds to weight, to position, to alcohol, and to airway anatomy — which is why the treatable components are worth taking seriously even for people who will never take this drug.
It is also not a reason to delay treating apnea you already have. A drug that takes a year to produce its effect does not address what your airway is doing tonight. The alternatives, ranked honestly.